1Lewin S, Walters T, Locarnini S. Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies. Antivir Res,2002,55: 381-396.
2Schneller SW. Carbocylic nucleosides (carbonucleosides) as new therapeutic leads. Curr Top Med Chem,2002:1087-1092.
3Marion PL, Salazar FH, Winters MA, et al. Potent effecacy of entecavir(BMS-200475) in a duck model of hepatitis B virus infection. Antimicrob Agents Chemother, 2002,46:82-88.
4Yamanaka G. Metabolic studies on BMS-200475,a new conpound active against hepatits B virus. Antimicrob Agents Chemother, 1999,43:190-193.
5Levine S. Efficacies of entecavir ngainst lamivudine-resistant hepatitis B virus replication and recombinatant polymerases in vitro. Antimicrob Agents Chemother, 2002,46: 2525-2532.
6Bifano M. Hepatic impairment does not alter single-does pharmacokinetics and safety of entecavir. Hepatology, 2004,40: ( 4 suppl. 1 ): 1149.
7Wolters LM, Hansen BE, Niesters HE, et al. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol,2002,37:137-144.
8Chang T. Sustained viral load and ALT reduction following 49 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine.Hepatology, 2002,36.
9Schiff ER. Entecavir 1.0 mg is consistently superior to lamivudine at 48 weeks across multiple baseline HBV disease characteristics in lamivudine refractory patients. Hepatology, 2004,40:(4 suppl. 1): 131.
10Chang T. Entecavir is superior to lamivudine for the treatment of HBeAg( + )chronic hepatitis B: results of phase Ⅲ study ETV-022 in nucleoside-naive patients. Hepatology, 2004,40:(4 suppl. 1): 193A.
